Sunday, July 13, 2008
By Steve Twedt, Pittsburgh Post-Gazette
With the Food and Drug Administration’s approval of a second fibromyalgia medication last month, you’d think the nation’s estimated 10 million acute pain fibromyalgia sufferers would be delighted.
While welcoming any new treatment, patients also know that insurance companies have been slow to cover Lyrica, which won FDA approval a year ago, and probably will have similar reluctance with Cymbalta, an antidepressant now approved for treating fibromyalgia. More…